Mallinckrodt acquires device for delivering immunotherapy for $1.3B

Mallinckrodt ($MNK) continued its wheeling and dealing with the planned $1.3 billion acquisition of Therakos, maker of a drug/device combination product that delivers immunotherapies to hospitalized patients. The move comes on the heels of the announcement of the sale of Mallinckrodt's contrast media and delivery systems business to Paris-based Guerbet for about $270 million. "Therakos is, quite simply, another excellent fit for Mallinckrodt. It is an immunotherapy treatment for patients who may have exhausted other therapies, with significant potential value in a variety of complex disease states and conditions. Installed in more than 350 academic medical centers and hospitals around the world, it is delivered in hospital-based out-patient clinics via an innovative, fully integrated, drug-device combination that is widely reimbursed globally," said Mallinckrodt CEO Mark Trudeau. More

Suggested Articles

The FDA will be working with government and public-private partners to distribute and evaluate 3D designs and models.

The FDA issued a wide-ranging emergency policy allowing alternative devices to be used as potentially lifesaving ventilators amid new shortages.

Hospitals in the New York City area are turning to a private distributor to airlift millions of protective masks out of China.